These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16623654)

  • 41. Attention-deficit/hyperactivity disorder: medication treatment-dosing and duration of action.
    Steinhoff KW
    Am J Manag Care; 2004 Jul; 10(4 Suppl):S99-106. PubMed ID: 15352536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder.
    Visser SN; Lesesne CA; Perou R
    Pediatrics; 2007 Feb; 119 Suppl 1():S99-106. PubMed ID: 17272592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
    Stasik D; Tucha O; Tucha L; Walitza S; Lange KW
    Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for management.
    Rostain AL
    Postgrad Med; 2008 Sep; 120(3):27-38. PubMed ID: 18824823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medications for adolescents with attention-deficit/hyperactivity disorder.
    Soileau EJ
    Adolesc Med State Art Rev; 2008 Aug; 19(2):254-67, viii-ix. PubMed ID: 18822831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Children's self-reports on perceived effects on taking stimulant medication for ADHD.
    Thorell LB; Dahlström K
    J Atten Disord; 2009 Mar; 12(5):460-8. PubMed ID: 18685139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
    Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
    Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder.
    Ashton H; Gallagher P; Moore B
    J Psychopharmacol; 2006 Sep; 20(5):602-10. PubMed ID: 16478756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical review: evidence-based diagnosis and treatment of ADHD in children.
    Nair J; Ehimare U; Beitman BD; Nair SS; Lavin A
    Mo Med; 2006; 103(6):617-21. PubMed ID: 17256270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of hyperactivity and attention deficit with amphetamine. Experience with five adult prisoners].
    Stovner AM; Wyller TB; Skulberg A; Os L; Korsmo G
    Tidsskr Nor Laegeforen; 1996 Jun; 116(17):2002-5. PubMed ID: 8766640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative EEG analysis in dexamphetamine-responsive adults with attention-deficit/hyperactivity disorder.
    Bresnahan SM; Barry RJ; Clarke AR; Johnstone SJ
    Psychiatry Res; 2006 Feb; 141(2):151-9. PubMed ID: 16343642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Attention-deficit/hyperactivity disorder and substance abuse.
    Harstad E; Levy S;
    Pediatrics; 2014 Jul; 134(1):e293-301. PubMed ID: 24982106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stimulants and the developing brain.
    Andersen SL
    Trends Pharmacol Sci; 2005 May; 26(5):237-43. PubMed ID: 15860370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study.
    Rose SR; Reeves G; Gut R; Germak J
    J Pediatr; 2015 Dec; 167(6):1389-96. PubMed ID: 26394822
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological treatment of adult ADHD in Europe.
    Retz W; Retz-Junginger P; Thome J; Rösler M
    World J Biol Psychiatry; 2011 Sep; 12 Suppl 1():89-94. PubMed ID: 21906003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
    Hammerness PG; Karampahtsis C; Babalola R; Alexander ME
    Expert Opin Drug Saf; 2015 Apr; 14(4):543-51. PubMed ID: 25648243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study.
    McCabe SE; Dickinson K; West BT; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2016 Jun; 55(6):479-86. PubMed ID: 27238066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.